Treatment of hair loss disorders with deuterated JAK inhibitors
US12285432B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 20, 2023 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Oct 20, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.